J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 7, Number 8, August 2015, pages 620-626

Predictive Factors for Non-Sentinel Lymph Node Metastasis in the Case of Positive Sentinel Lymph Node Metastasis in Two or Fewer Nodes in Breast Cancer

Figure 1. Association between invasive tumor size and non-sentinel lymph node (SLN) metastasis (n = 44). Invasive tumor size was significantly larger in patients who were positive for non-SLN metastasis compared with those who were negative (median size 35.0 vs. 20 mm, respectively; P = 0.020).

Figure 2. Receiver operating characteristic (ROC) analysis of invasive tumor size (n = 44). The ROC analysis identified a cut-off point of 28 mm (area under the curve 0.709; sensitivity 64.7%; specificity 25.9%; P = 0.021).

**Table 1.** Association Between Non-Sentinel Lymph Node Metastasis and Clinicopathological Features (n = 44)
Characteristics	No. of patients	Non-SLN metastasis	P value
SLN: sentinel lymph node; ER: estrogen receptor; PR: progesterone receptor.
Age (years)				> 0.999
≤ 50	25	15 (60.0)	10 (40.0)
> 50	19	12 (63.2)	7 (36.8)
Invasive tumor size (mm)				0.062
≤ 20	22	17 (77.3)	5 (22.7)
> 20	22	10 (45.5)	12 (54.5)
Histological grade				0.108
I	28	20 (71.4)	8 (28.6)
II-III	16	7 (43.8)	9 (56.2)
Lymphatic involvement				0.035
Negative	32	23 (71.9)	9 (28.1)
Positive	12	4 (33.3)	8 (66.7)
Venous involvement				> 0.999
Negative	37	23 (62.2)	14 (37.8)
Positive	7	4 (57.1)	3 (42.9)
ER and/or PR				> 0.999
Negative	3	2 (66.7)	1 (33.3)
Positive	41	25 (61.0)	16 (39.0)
HER2				> 0.999
Negative	36	22 (61.1)	14 (38.9)
Positive	8	5 (62.5)	3 (37.5)
Molecular subtype				0.867
Luminal A	33	20 (60.6)	13 (39.4)
Luminal B	7	4 (57.1)	3 (42.9)
HER2	1	1 (100)	0 (0)
Triple negative	3	2 (66.7)	1 (33.3)
Ki-67 labeling index				0.359
< 14%	25	17 (68.0)	8 (32.0)
≥ 14%	19	10 (52.6)	9 (47.4)

Table 1. Association Between Non-Sentinel Lymph Node Metastasis and Clinicopathological Features (n = 44)

Characteristics

No. of patients

Non-SLN metastasis

P value

Negative (%)

Positive (%)

SLN: sentinel lymph node; ER: estrogen receptor; PR: progesterone receptor.

Age (years)

> 0.999

≤ 50

15 (60.0)

10 (40.0)

> 50

12 (63.2)

7 (36.8)

Invasive tumor size (mm)

0.062

≤ 20

17 (77.3)

5 (22.7)

> 20

10 (45.5)

12 (54.5)

Histological grade

0.108

20 (71.4)

8 (28.6)

II-III

7 (43.8)

9 (56.2)

Lymphatic involvement

0.035

Negative

23 (71.9)

9 (28.1)

Positive

4 (33.3)

8 (66.7)

Venous involvement

> 0.999

Negative

23 (62.2)

14 (37.8)

Positive

4 (57.1)

3 (42.9)

ER and/or PR

> 0.999

Negative

2 (66.7)

1 (33.3)

Positive

25 (61.0)

16 (39.0)

HER2

> 0.999

Negative

22 (61.1)

14 (38.9)

Positive

5 (62.5)

3 (37.5)

Molecular subtype

0.867

Luminal A

20 (60.6)

13 (39.4)

Luminal B

4 (57.1)

3 (42.9)

HER2

1 (100)

0 (0)

Triple negative

2 (66.7)

1 (33.3)

Ki-67 labeling index

0.359

< 14%

17 (68.0)

8 (32.0)

≥ 14%

10 (52.6)

9 (47.4)

**Table 2.** Non-Sentinel Lymph Node Metastasis and Cut-Off Points of Invasive Tumor Size (n = 44)
Invasive tumor size	No. of patients	Non-SLN metastasis	P value
SLN: sentinel lymph node.
Cut-off point 20 mm				0.062
≤ 20 mm	22	17 (77.3)	5 (22.7)
> 20 mm	22	10 (45.5)	12 (54.5)
Cut-off point 28 mm				0.015
≤ 28 mm	26	20 (76.9)	6 (23.1)
> 28 mm	18	7 (38.9)	11 (61.1)

Table 2. Non-Sentinel Lymph Node Metastasis and Cut-Off Points of Invasive Tumor Size (n = 44)

Invasive tumor size

No. of patients

Non-SLN metastasis

P value

Negative (%)

Positive (%)

SLN: sentinel lymph node.

Cut-off point 20 mm

0.062

≤ 20 mm

17 (77.3)

5 (22.7)

> 20 mm

10 (45.5)

12 (54.5)

Cut-off point 28 mm

0.015

≤ 28 mm

20 (76.9)

6 (23.1)

> 28 mm

7 (38.9)

11 (61.1)

**Table 3.** Multivariate Analysis of Clinicopathological Factors (n = 44)
Variable	RR (95% CI)	P value
RR: relative risk; CI: confidence interval.
Lymphatic involvement
Negative	1.000
Positive	7.255 (1.388 - 37.929)	0.019
Invasive tumor size
≤ 28 mm	1.000
> 28 mm	7.083 (1.560 - 32.153)	0.011

Table 3. Multivariate Analysis of Clinicopathological Factors (n = 44)

Variable

RR (95% CI)

P value

RR: relative risk; CI: confidence interval.

Lymphatic involvement

Negative

1.000

Positive

7.255 (1.388 - 37.929)

0.019

Invasive tumor size

≤ 28 mm

1.000

> 28 mm

7.083 (1.560 - 32.153)

0.011